# Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

> **NCT04336410** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** INO-4800
- **DEVICE:** CELLECTRA® 2000

## Key facts

- **NCT ID:** NCT04336410
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-03
- **Primary completion:** 2022-02-10
- **Final completion:** 2022-02-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04336410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04336410, "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04336410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*